{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:17:49Z","timestamp":1793823469858,"version":"4.6.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.hoc.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T14:53:42Z","timestamp":1685631222000},"page":"809-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology"],"prefix":"10.1016","volume":"37","author":[{"given":"Nitin H.","family":"Shirole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William G.","family":"Kaelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib2","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"36","key":"10.1016\/j.hoc.2023.04.011_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and Risk Factors for Kidney Cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G","article-title":"The Heidelberg classification of renal cell tumours","volume":"183","author":"Kovacs","year":"1997","journal-title":"J\u00a0Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.011_bib6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"7456","key":"10.1016\/j.hoc.2023.04.011_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma","volume":"374","author":"Cancer Genome Atlas Research","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ucl.2008.07.014","article-title":"Familial and hereditary renal cancer syndromes","volume":"35","author":"Coleman","year":"2008","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2010.08.031","article-title":"Hereditary renal cancer syndromes: an update of a systematic review","volume":"58","author":"Verine","year":"2010","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ccr.2004.09.006","article-title":"Focus on kidney cancer","volume":"6","author":"Linehan","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jmg.2005.033506","article-title":"Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer","volume":"43","author":"Wei","year":"2006","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2010.01486.x","article-title":"Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis","volume":"79","author":"Smit","year":"2011","journal-title":"Clin Genet"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1001\/archdermatol.2008.517","article-title":"Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer","volume":"144","author":"Stewart","year":"2008","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib19","first-page":"1482","article-title":"Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome","volume":"173","author":"Pavlovich","year":"2005","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib20","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1001\/archderm.1977.01640120042005","article-title":"Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons","volume":"113","author":"Birt","year":"1977","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib21","first-page":"45","article-title":"Hereditary multiple fibrofolliculomas, trichodiscomas and acrochordons: syndrome of Birt-Hogg-Dube","volume":"11","author":"Scalvenzi","year":"1998","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.011_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.011_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A\u00a0novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/jmedgenet-2014-102912","article-title":"A\u00a0germline mutation in PBRM1 predisposes to renal cell carcinoma","volume":"52","author":"Benusiglio","year":"2015","journal-title":"J\u00a0Med Genet"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005792-199711000-00001","article-title":"von Hippel-Lindau disease","volume":"76","author":"Maher","year":"1997","journal-title":"Medicine (Baltim)"},{"issue":"18","key":"10.1016\/j.hoc.2023.04.011_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162480","article-title":"Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer","volume":"132","author":"Kaelin","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2023.04.011_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.pathol.2.010506.092049","article-title":"Von Hippel-Lindau disease","volume":"2","author":"Kaelin","year":"2007","journal-title":"Annu Rev Pathol"},{"issue":"6161","key":"10.1016\/j.hoc.2023.04.011_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","article-title":"Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma","volume":"332","author":"Seizinger","year":"1988","journal-title":"Nature"},{"issue":"5112","key":"10.1016\/j.hoc.2023.04.011_bib30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.hoc.2023.04.011_bib31","doi-asserted-by":"crossref","first-page":"9700","DOI":"10.1073\/pnas.91.21.9700","article-title":"Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma","volume":"91","author":"Herman","year":"1994","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.011_bib32","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of VHL gene mutation in human cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.011_bib33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/hmg\/3.8.1303","article-title":"Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype","volume":"3","author":"Crossey","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","article-title":"Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype","volume":"5","author":"Chen","year":"1995","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2214\/ajr.159.6.1442389","article-title":"The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients","volume":"159","author":"Choyke","year":"1992","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2012.02.025","article-title":"Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor","volume":"148","author":"Xu","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.011_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13059-014-0433-z","article-title":"Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution","volume":"15","author":"Fisher","year":"2014","journal-title":"Genome Biol"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib39","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cam4.293","article-title":"The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling","volume":"3","author":"Sankin","year":"2014","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib41","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","article-title":"Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer","volume":"66","author":"Banks","year":"2006","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.hoc.2023.04.011_bib42","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.04.011_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1101\/sqb.2016.81.030833","article-title":"Targeting HIF2 in Clear Cell Renal Cell Carcinoma","volume":"81","author":"Cho","year":"2016","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.011_bib44","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/0008-5472.CAN-09-0146","article-title":"Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney","volume":"69","author":"Beroukhim","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib45","first-page":"2010","article-title":"Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications","volume":"154","author":"Walther","year":"1995","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib46","first-page":"2089","article-title":"Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients","volume":"149","author":"Lubensky","year":"1996","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/PAS.0b013e3181ddf54d","article-title":"VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease","volume":"34","author":"Montani","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.011_bib48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.1014","article-title":"Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma","volume":"44","author":"Guo","year":"2011","journal-title":"Nat Genet"},{"issue":"7331","key":"10.1016\/j.hoc.2023.04.011_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.011_bib51","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"issue":"7279","key":"10.1016\/j.hoc.2023.04.011_bib52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"issue":"5229","key":"10.1016\/j.hoc.2023.04.011_bib53","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.7660130","article-title":"Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C","volume":"269","author":"Kibel","year":"1995","journal-title":"Science"},{"issue":"5414","key":"10.1016\/j.hoc.2023.04.011_bib54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.284.5414.657","article-title":"Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase","volume":"284","author":"Kamura","year":"1999","journal-title":"Science"},{"issue":"5229","key":"10.1016\/j.hoc.2023.04.011_bib55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1126\/science.7660122","article-title":"Inhibition of transcription elongation by the VHL tumor suppressor protein","volume":"269","author":"Duan","year":"1995","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib56","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","article-title":"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins","volume":"94","author":"Pause","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1128\/MCB.18.2.732","article-title":"Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B\/C and Cul2","volume":"18","author":"Lonergan","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.hoc.2023.04.011_bib58","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1073\/pnas.96.22.12436","article-title":"Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex","volume":"96","author":"Iwai","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"33","key":"10.1016\/j.hoc.2023.04.011_bib59","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein","volume":"275","author":"Cockman","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"16","key":"10.1016\/j.hoc.2023.04.011_bib60","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","article-title":"Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein","volume":"19","author":"Tanimoto","year":"2000","journal-title":"EMBO J"},{"issue":"19","key":"10.1016\/j.hoc.2023.04.011_bib61","doi-asserted-by":"crossref","first-page":"10430","DOI":"10.1073\/pnas.190332597","article-title":"Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex","volume":"97","author":"Kamura","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.011_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"issue":"5413","key":"10.1016\/j.hoc.2023.04.011_bib63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","article-title":"Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function","volume":"284","author":"Stebbins","year":"1999","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib65","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1357-2725(03)00211-5","article-title":"The mammalian basic helix-loop-helix\/PAS family of transcriptional regulators","volume":"36","author":"Kewley","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrc3621","article-title":"bHLH-PAS proteins in cancer","volume":"13","author":"Bersten","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia--a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"5516","key":"10.1016\/j.hoc.2023.04.011_bib69","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"issue":"5516","key":"10.1016\/j.hoc.2023.04.011_bib70","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.hoc.2023.04.011_bib71","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1073\/pnas.181341498","article-title":"HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation","volume":"98","author":"Yu","year":"2001","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib73","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.molcel.2017.06.002","article-title":"The EGLN-HIF O(2)-Sensing System: Multiple Inputs and Feedbacks","volume":"66","author":"Ivan","year":"2017","journal-title":"Mol Cell"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.011_bib74","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.011_bib75","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1091\/mbc.e06-05-0419","article-title":"The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha","volume":"18","author":"Hu","year":"2007","journal-title":"Mol Biol Cell"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib76","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1096\/fj.04-1640fje","article-title":"Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells","volume":"18","author":"Warnecke","year":"2004","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib77","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in\u00a0vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"21","key":"10.1016\/j.hoc.2023.04.011_bib78","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1128\/MCB.00331-09","article-title":"A\u00a0feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in\u00a0vivo","volume":"29","author":"Minamishima","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"32","key":"10.1016\/j.hoc.2023.04.011_bib80","doi-asserted-by":"crossref","first-page":"22575","DOI":"10.1074\/jbc.M600288200","article-title":"Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment","volume":"281","author":"Bracken","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib81","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/MCB.01514-06","article-title":"The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in\u00a0vivo","volume":"27","author":"Yan","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.011_bib82","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.32","article-title":"Common pitfalls in preclinical cancer target validation","volume":"17","author":"Kaelin","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib83","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.1617608","article-title":"Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling","volume":"22","author":"DeYoung","year":"2008","journal-title":"Genes Dev"},{"issue":"23","key":"10.1016\/j.hoc.2023.04.011_bib84","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev"},{"issue":"23","key":"10.1016\/j.hoc.2023.04.011_bib85","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1101\/gad.322704","article-title":"The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila","volume":"18","author":"Reiling","year":"2004","journal-title":"Genes Dev"},{"issue":"49","key":"10.1016\/j.hoc.2023.04.011_bib86","doi-asserted-by":"crossref","first-page":"35803","DOI":"10.1074\/jbc.M705231200","article-title":"Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb","volume":"282","author":"Li","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(03)00194-6","article-title":"The hypoxic response of tumors is dependent on their microenvironment","volume":"4","author":"Blouw","year":"2003","journal-title":"Cancer Cell"},{"issue":"6692","key":"10.1016\/j.hoc.2023.04.011_bib89","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","article-title":"Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis","volume":"394","author":"Carmeliet","year":"1998","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.011_bib90","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2014-04-567065","article-title":"HIF-1alpha can act as a tumor suppressor gene in murine acute myeloid leukemia","volume":"124","author":"Velasco-Hernandez","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib91","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41467-021-21687-2","article-title":"Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response","volume":"12","author":"Andrysik","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.011_bib92","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0895-822","article-title":"Tumour suppression by the human von Hippel-Lindau gene product","volume":"1","author":"Iliopoulos","year":"1995","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib93","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib94","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1541-7786.89.2.2","article-title":"Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-\/- tumors","volume":"2","author":"Zimmer","year":"2004","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","article-title":"Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein","volume":"1","author":"Kondo","year":"2002","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.hoc.2023.04.011_bib96","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","article-title":"Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma","volume":"25","author":"Raval","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib97","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","article-title":"The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma","volume":"1","author":"Maranchie","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib98","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","article-title":"Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene","volume":"1","author":"Shen","year":"2011","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.011_bib99","first-page":"4337","article-title":"Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma","volume":"29","author":"Morris","year":"2009","journal-title":"Anticancer Res"},{"issue":"7627","key":"10.1016\/j.hoc.2023.04.011_bib100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"7627","key":"10.1016\/j.hoc.2023.04.011_bib101","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.hoc.2023.04.011_bib102","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120403119","article-title":"Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway","volume":"119","author":"Stransky","year":"2022","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib103","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib104","doi-asserted-by":"crossref","first-page":"e31034","DOI":"10.1371\/journal.pone.0031034","article-title":"Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts","volume":"7","author":"Schietke","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1619726114","article-title":"Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-\/- clear cell renal carcinoma","volume":"114","author":"Gao","year":"2017","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib106","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","article-title":"The SWI\/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma","volume":"18","author":"Nargund","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/2326-6066.CIR-21-0480","article-title":"PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner","volume":"10","author":"Zhou","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib108","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/ng.723","article-title":"Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3","volume":"43","author":"Purdue","year":"2011","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib109","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/jcp.2003.012963","article-title":"Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours","volume":"57","author":"Jubb","year":"2004","journal-title":"J\u00a0Clin Pathol"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.011_bib110","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.hoc.2023.04.011_bib111","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/sj.onc.1206373","article-title":"Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor","volume":"22","author":"Baba","year":"2003","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.hoc.2023.04.011_bib112","first-page":"3803","article-title":"Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease","volume":"62","author":"Zatyka","year":"2002","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.011_bib113","first-page":"3014","article-title":"VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells","volume":"62","author":"Bindra","year":"2002","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.011_bib114","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.bjc.6601657","article-title":"Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene","volume":"90","author":"Wykoff","year":"2004","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.011_bib115","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1002\/j.1460-2075.1996.tb01097.x","article-title":"The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A\/E-Cdk2","volume":"15","author":"Kitagawa","year":"1996","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.011_bib116","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0092-8674(93)90136-E","article-title":"Functional interactions of the retinoblastoma protein with mammalian D-type cyclins","volume":"73","author":"Ewen","year":"1993","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.011_bib117","doi-asserted-by":"crossref","first-page":"e80544","DOI":"10.1371\/journal.pone.0080544","article-title":"The contributions of HIF-target genes to tumor growth in RCC","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"issue":"43","key":"10.1016\/j.hoc.2023.04.011_bib118","doi-asserted-by":"crossref","first-page":"16484","DOI":"10.1073\/pnas.0806574105","article-title":"Kinase requirements in human cells: III. Altered kinase requirements in VHL-\/- cancer cells detected in a pilot synthetic lethal screen","volume":"105","author":"Bommi-Reddy","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"601","key":"10.1016\/j.hoc.2023.04.011_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay0482","article-title":"HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species","volume":"12","author":"Nicholson","year":"2019","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib120","first-page":"1387","article-title":"Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-\/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis","volume":"98","author":"de Paulsen","year":"2001","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.011_bib121","doi-asserted-by":"crossref","first-page":"e23936","DOI":"10.1371\/journal.pone.0023936","article-title":"The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.hoc.2023.04.011_bib122","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1073\/pnas.1112129109","article-title":"Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1","volume":"109","author":"Wang","year":"2012","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib123","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/0008-5472.CAN-05-0169","article-title":"Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-\/- renal cancer","volume":"65","author":"Smith","year":"2005","journal-title":"Cancer Res"},{"issue":"50","key":"10.1016\/j.hoc.2023.04.011_bib124","doi-asserted-by":"crossref","first-page":"21306","DOI":"10.1073\/pnas.0906432106","article-title":"Human cancers converge at the HIF-2alpha oncogenic axis","volume":"106","author":"Franovic","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.011_bib125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.onc.1208181","article-title":"Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor\/scatter factor","volume":"24","author":"Zhang","year":"2005","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.011_bib126","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.011_bib127","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","article-title":"A\u00a0phase I study of cabozantinib (XL184) in patients with renal cell cancer","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nchembio.1185","article-title":"Allosteric inhibition of hypoxia inducible factor-2 with small molecules","volume":"9","author":"Scheuermann","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib129","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1073\/pnas.0808092106","article-title":"Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor","volume":"106","author":"Scheuermann","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib130","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm301847z","article-title":"Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor","volume":"56","author":"Rogers","year":"2013","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.011_bib131","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.hoc.2023.04.011_bib132","doi-asserted-by":"crossref","first-page":"9691","DOI":"10.1021\/acs.jmedchem.8b01196","volume":"61","author":"Wehn","year":"2018","journal-title":"J\u00a0Med Chem"},{"issue":"18","key":"10.1016\/j.hoc.2023.04.011_bib133","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A\u00a0Small-Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.hoc.2023.04.011_bib134","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2alpha (HIF-2alpha) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma","volume":"62","author":"Xu","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.011_bib135","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2alpha Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib136","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.hoc.2023.04.011_bib137","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.011_bib138","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2021.1925248","article-title":"MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma","volume":"30","author":"Hasanov","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.011_bib139","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia Inducible factor 2 alpha (HIF2alpha) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2022","journal-title":"Endocr Rev"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.011_bib140","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1158\/1078-0432.CCR-22-0963","article-title":"HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans","volume":"28","author":"Ma","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.011_bib141","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.18632\/oncotarget.561","article-title":"Targeting HIF2alpha translation with Tempol in VHL-deficient clear cell renal cell carcinoma","volume":"3","author":"Sourbier","year":"2012","journal-title":"Oncotarget"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882300045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882300045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:21:38Z","timestamp":1760185298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882300045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":141,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S088985882300045X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}